The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Quality by design for biopharmaceuticals
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control
Yu, L. X. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9511-1 · Cited by 1,191
Mire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624
Applications of process analytical technology to crystallization processes
Yu, L. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.012 · Cited by 323
Gupta, S., Indelicato, S. R., Jethwa, V., Kawabata, T., Kelley, M., Mire-Sluis, A. R., Richards, S. M., Rup, B., Shores, E., Swanson, S. J., et al. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.12.004 · Cited by 241
Current and future issues in the manufacturing and development of monoclonal antibodies
Kozlowski, S., & Swann, P. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.002 · Cited by 170
Gnoth, S., Jenzsch, M., Simutis, R., & Lübbert, A. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.03.020 · Cited by 127
Rathore, A. S., Yu, M., Yeboah, S., & Sharma, A. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21759 · Cited by 126
Self-citationKirdar, A. O., Green, K. D., & Rathore, A. S. (2008) · Biotechnology Progress · doi:10.1021/bp0704384 · Cited by 104
Self-citationKirdar, A. O., Conner, J. S., Baclaski, J., & Rathore, A. S. (2007) · Biotechnology Progress · doi:10.1021/bp060377u · Cited by 102
Self-citationDefining Process Design Space for Biotech Products: Case Study of Pichia pastoris Fermentation
Harms, J., Wang, X., Kim, T., Yang, X., & Rathore, A. S. (2008) · Biotechnology Progress · doi:10.1021/bp070338y · Cited by 101
Self-citation
Cited by
Understanding pharmaceutical quality by design
Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9598-3 · Cited by 1,475
Optimal and consistent protein glycosylation in mammalian cell culture
Hossler, P., Khattak, S. F., & Li, Z. J. (2009) · Glycobiology · doi:10.1093/glycob/cwp079 · Cited by 669
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Design of experiments (DoE) in pharmaceutical development
N. Politis, S., Colombo, P., Colombo, G., & M. Rekkas, D. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1291672 · Cited by 597
Spray drying formulation of amorphous solid dispersions
Singh, A., & Van den Mooter, G. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.010 · Cited by 526
Aggregates in monoclonal antibody manufacturing processes
Vázquez‐Rey, M., & Lang, D. A. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23155 · Cited by 479
The Future of Pharmaceutical Manufacturing Sciences
Rantanen, J., & Khinast, J. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24594 · Cited by 442
Roadmap for implementation of quality by design (QbD) for biotechnology products
Rathore, A. S. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.06.006 · Cited by 411
Self-citationAn overview of experimental designs in HPLC method development and validation
Sahu, P. K., Ramisetti, N. R., Cecchi, T., Swain, S., Patro, C. S., & Panda, J. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.05.006 · Cited by 392
Pandi, P., Bulusu, R., Kommineni, N., Khan, W., & Singh, M. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119560 · Cited by 391
Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
Ragelle, H., Danhier, F., Préat, V., Langer, R., & Anderson, D. G. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1244187 · Cited by 390
Process analytical technology (PAT) for biopharmaceutical products
Rathore, A. S., Bhambure, R., & Ghare, V. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3781-x · Cited by 368
Self-citationBCS class IV drugs: Highly notorious candidates for formulation development
Ghadi, R., & Dand, N. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.014 · Cited by 361
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Quality cell therapy manufacturing by design
Lipsitz, Y. Y., Timmins, N. E., & Zandstra, P. W. (2016) · Nature Biotechnology · doi:10.1038/nbt.3525 · Cited by 311
Fernández-García, R., Lalatsa, A., Statts, L., Bolás-Fernández, F., Ballesteros, M. P., & Serrano, D. R. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118817 · Cited by 289
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
Agrahari, V., & Agrahari, V. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.047 · Cited by 253
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Rogers, R. S., Nightlinger, N. S., Livingston, B., Campbell, P., Bailey, R., & Balland, A. (2015) · mAbs · doi:10.1080/19420862.2015.1069454 · Cited by 231
Lauber, M. A., Yu, Y.-Q., Brousmiche, D. W., Hua, Z., Koza, S. M., Magnelli, P., Guthrie, E., Taron, C. H., & Fountain, K. J. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00758 · Cited by 211
Fisher, A. C., Kamga, M.-H., Agarabi, C., Brorson, K., Lee, S. L., & Yoon, S. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.08.008 · Cited by 180
Bioprocess Control: Current Progress and Future Perspectives
Rathore, A. S., Mishra, S., Nikita, S., & Priyanka, P. (2021) · Life · doi:10.3390/life11060557 · Cited by 141
Self-citationJimenez del Val, I., Nagy, J. M., & Kontoravdi, C. (2011) · Biotechnology Progress · doi:10.1002/btpr.688 · Cited by 135
“the Quality by Design (QbD) paradigm to the manufacture of biopharmaceuticals.(9) Implementation of QbD requires the”
BackgroundMethodModern Sensor Tools and Techniques for Monitoring, Controlling, and Improving Cell Culture Processes
Reyes, S. J., Durocher, Y., Pham, P. L., & Henry, O. (2022) · Processes · doi:10.3390/pr10020189 · Cited by 130
Fluorescence Spectroscopy and Chemometric Modeling for Bioprocess Monitoring
Faassen, S., & Hitzmann, B. (2015) · Sensors · doi:10.3390/s150510271 · Cited by 120
Generic Raman‐based calibration models enabling real‐time monitoring of cell culture bioreactors
Mehdizadeh, H., Lauri, D., Karry, K. M., Moshgbar, M., Procopio‐Melino, R., & Drapeau, D. (2015) · Biotechnology Progress · doi:10.1002/btpr.2079 · Cited by 108
Challenges in the Development of Soft Sensors for Bioprocesses: A Critical Review
Brunner, V., Siegl, M., Geier, D., & Becker, T. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.722202 · Cited by 100
“With the introduction of the quality by design (QbD) and process analytical technology (PAT) initiatives, this development has received institutional support (FDA, 2004; Rathore and Winkle, 2009).”
MethodOn-line soft sensing in upstream bioprocessing
Randek, J., & Mandenius, C.-F. (2018) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1312271 · Cited by 86
Jedrzejewski, P., Del Val, I., Constantinou, A., Dell, A., Haslam, S., Polizzi, K., & Kontoravdi, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034492 · Cited by 83
Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation
Hamrang, Z., Rattray, N. J. W., & Pluen, A. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.05.004 · Cited by 75
Thakur, G., Hebbi, V., & Rathore, A. S. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27236 · Cited by 64
Self-citationScale‐Down Model Development in ambr systems: An Industrial Perspective
Sandner, V., Pybus, L. P., McCreath, G., & Glassey, J. (2019) · Biotechnology Journal · doi:10.1002/biot.201700766 · Cited by 63
Rafferty, C., Johnson, K., O'Mahony, J., Burgoyne, B., Rea, R., & Balss, K. M. (2020) · Biotechnology Progress · doi:10.1002/btpr.2977 · Cited by 63
Engineering Challenges in Therapeutic Protein Product and Process Design
Papathanasiou, M. M., & Kontoravdi, C. (2020) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2019.11.010 · Cited by 57
Nagashima, H., Watari, A., Shinoda, Y., Okamoto, H., & Takuma, S. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23744 · Cited by 52
Tescione, L., Lambropoulos, J., Paranandi, M. R., Makagiansar, H., & Ryll, T. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25330 · Cited by 46
“More recently this has been done using risk-based approaches (International Conference on Harmonization, 2006; US Food and Drug Administration, 2006) following the Quality by Design (QbD) paradigm (Banerjee, 2010; Rathore and Winkle, 2009; Shivhare and McCreath, 2010).”
MethodContinuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?
Rathore, A. S., Thakur, G., & Kateja, N. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28235 · Cited by 41
Self-citationGlycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
Exposing the molecular heterogeneity of glycosylated biotherapeutics
Schachner, L. F., Mullen, C., Phung, W., Hinkle, J. D., Beardsley, M. I., Bentley, T., Day, P., Tsai, C., Sukumaran, S., Baginski, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47693-8 · Cited by 36
Madabhushi, S. R., Podtelezhnikov, A. A., Murgolo, N., Xu, S., & Lin, H. (2021) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2021.01.023 · Cited by 27
Simone, E., Zhang, W., & Nagy, Z. K. (2016) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.4743 · Cited by 24
QbD Based Media Development for the Production of Fab Fragments in E. coli
Kumar, D., Batra, J., Komives, C., & Rathore, A. S. (2019) · Bioengineering · doi:10.3390/bioengineering6020029 · Cited by 24
Self-citationProcess analytics 4.0: A paradigm shift in rapid analytics for biologics development
Wasalathanthri, D. P., Shah, R., Ding, J., Leone, A., & Li, Z. J. (2021) · Biotechnology Progress · doi:10.1002/btpr.3177 · Cited by 17
Metadata
- Authors
- Rathore, A. S., & Winkle, H.
- Venue
- Nature Biotechnology
- Published
- 2009-01
- Volume
- 27
- Issue
- 1
- Pages
- 26-34
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2077285487
- Cited by
- 830
- References
- 10
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.